PD-153035 hydrochloride : A hydrochloride obtained by combining PD-153035 with one equivalent of hydrochloric acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 11246488 |
| CHEMBL ID | 1204168 |
| CHEBI ID | 91075 |
| SCHEMBL ID | 93918 |
| MeSH ID | M0277434 |
| Synonym |
|---|
| chembl1204168 , |
| HY-12013 |
| pd153035 (hydrochloride) |
| su 5271 |
| ag 1517 |
| SR-01000597835 , |
| pd 153035 hydrochloride |
| AKOS003077033 |
| EX-3384 |
| PD153035 HYDROCHLORIDE , |
| PD153035 HCL , |
| tyrphostin ag 1517 |
| zm 252868 |
| 4-quinazolinamine, n-(3-bromophenyl)-6,7-dimethoxy-, hydrochloride (1:1) |
| pd-153035 hydrochloride |
| ag 1517 hydrochloride |
| ahj252p69n , |
| su-5271 hydrochloride |
| unii-ahj252p69n |
| CS-0142 |
| S1079 |
| ag-1517 hydrochloride |
| 6,7-dimethoxy-4-(n-(3-bromophenyl)amino)quinazoline hydrochloride |
| 4-quinazolinamine, n-(3-bromophenyl)-6,7-dimethoxy-, monohydrochloride |
| whi-p-79 hydrochloride |
| n-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride |
| 183322-45-4 |
| 4-[(3-bromophenyl)amino]-6,7-dimethoxyquinazoline hydrochloride |
| 6,7-dimethoxy-4-[n-(3-bromophenyl)amino]quinazoline hydrochloride |
| SCHEMBL93918 |
| smr004702867 |
| MLS006011079 |
| CHEBI:91075 |
| n-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-aminium chloride |
| pd-153035.hcl |
| pd153035.hcl |
| pd 153035.hcl |
| n-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine;hydrochloride |
| B4945 |
| AC-29959 |
| DTXSID30171414 |
| J-518170 |
| pd153035hcl |
| EX-A220 |
| zm 252868 hcl |
| SR-01000597835-1 |
| mfcd01074805 |
| n-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine hcl |
| pd153035 hydrochloride, >=98% (hplc) |
| J-011739 |
| pd153035 hcl (su-5271, ag1517) |
| 183322-45-4 (hcl) |
| BCP16320 |
| pd-153035 hcl |
| Q27163046 |
| FT-0711790 |
| BS-16156 |
| n-(3-bromophenyl)-6,7-dimethoxy-4-quinazolinamine hydrochloride |
| 4-quinazolinamine, n-(3-bromophenyl)-6,7-dimethoxy-, hydrochloride (1:?) |
| 205195-07-9 |
| n-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-aminehydrochloride |
| pd153035 (hydrochloride);su-5271 (hydrochloride); ag1517 (hydrochloride); zm 252868 (hydrochloride) |
| Role | Description |
|---|---|
| epidermal growth factor receptor antagonist | An antagonist at the epidermal growth factor receptor. |
| EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0714 | 0.0000 | 0.5369 | 10.0000 | AID283008; AID283009; AID283012 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | IC50 (µMol) | 0.1430 | 0.0001 | 0.5453 | 10.0000 | AID283010 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | IC50 (µMol) | 0.0490 | 0.0001 | 0.1736 | 2.5900 | AID283011 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| AID283008 | Displacement of [125I]4-(3-iodoanilino)-6,7-dimethoxyquinazoline from EGFR tyrosine kinase in human A431 cell membranes | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283013 | Inhibition of DNA synthesis in EGF-independent human MCF7 cells assessed as 3H]thymidine incorporation | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283010 | Inhibition of human ErbB2 tyrosine kinase phosphorylation expressed in mouse BaF3 cells | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283014 | Ratio of IC50 for human MCF7 cells to IC50 for human MCF10A cells | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283011 | Inhibition of human ErbB4 tyrosine kinase phosphorylation expressed in human CEM/4 cells | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283012 | Inhibition of DNA synthesis in EGF-dependent human MCF10A cells assessed as [3H]thymidine incorporation | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283009 | Inhibition of human EGFR tyrosine kinase phosphorylation expressed in mouse BaF3 cells | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| AID283007 | Lipophilicity, log P of the compound | 2005 | Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23 | Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.60) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||